ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Colorectal Cancer Test Completion among Adults Aged 45 to 75 in an Integrated Healthcare System: A Retrospective Analysis.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modifiable risk factors contributing to the rising incidence of early-onset colorectal cancer in the United States over three decades: a Global Burden of Disease analysis.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIn 2021, the US Preventive Services Task Force (USPSTF) lowered the recommended age for colorectal cancer screening from 50 to 45 years. This study examined colorectal cancer test completion and test modalities used among adults 45 to 49 years of age compared with those 50 years and older.
methodsWe conducted a retrospective cohort study using electronic health records from an integrated academic-community health system that implemented organized screening. Adults 45 to 75 years of age eligible for colorectal cancer screening between 2021 and 2024 were included. Outcomes were colorectal cancer test completion and test modality: colonoscopy, fecal immunochemical test (FIT), FIT-DNA, CT colonography, or flexible sigmoidoscopy.
resultsApproximately 80,000 adults were eligible for screening annually. Colorectal cancer test completion increased from 61.8% (2021) to 70.8% (2024), with the largest increase in the 45- to 49-year age group (25.6% to 51.7%). Colonoscopy and FIT were the most used modalities; among 45 to 49 year olds, FIT increased by 12.2% and colonoscopy by 14.2%. FIT-DNA use increased slightly, whereas flexible sigmoidoscopy use declined. Racial and ethnic disparities in colorectal cancer test completion decreased across groups.
conclusionsFollowing the 2021 USPSTF recommendation, colorectal cancer test completion improved across all age groups, especially in adults 45 to 49 years of age. Colonoscopy and FIT use predominated. Ongoing efforts are needed to improve screening among younger adults to reach the 80% national screening goal. IMPACT: This study demonstrated that expanding colorectal cancer testing to 45 to 49 year olds led to increased uptake of colonoscopy and FIT. It highlights how organized outreach and providing options in screening modalities can improve colorectal cancer test completion across several patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.